Neoadjuvant Endocrine Therapy in Clinical Practice-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Neoadjuvant Endocrine Therapy in Clinical Practice

Published:2021-11-01 Issue:11 Volume:7 Page:1700
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Sella Tal¹²,Weiss Anna²³,Mittendorf Elizabeth A.²³,King Tari A.²³,Pilewskie Melissa⁴,Giuliano Armando E.⁵,Metzger-Filho Otto¹²

Affiliation:

1. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

2. Breast Oncology Program, Dana-Farber/Brigham and Women’s Cancer Center, Boston, Massachusetts

3. Division of Breast Surgery, Department of Surgery, Brigham and Women’s Hospital, Boston, Massachusetts

4. Breast Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York

5. Division of Surgical Oncology, Department of Surgery, Cedars-Sinai Health System, Los Angeles, California

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2783593/jamaoncology_sella_2021_rv_210006_1636656329.42814.pdf

Reference75 articles.

1. Surgery versus primary endocrine therapy for elderly women with operable primary breast cancer.;Morgan;Cochrane Database Syst Rev,2014

2. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study.;Eiermann;Ann Oncol,2001

3. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.;Smith;J Clin Oncol,2005

4. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative “Arimidex” Compared to Tamoxifen (PROACT) trial.;Cataliotti;Cancer,2006

5. Current status of neoadjuvant endocrine therapy in early stage breast cancer.;Reinert;Curr Treat Options Oncol,2018

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot study;2024-09-01

2. Neoadjuvant Therapy: Current Landscape and Future Horizons for ER-Positive/HER2-Negative and Triple-Negative Early Breast Cancer;Current Treatment Options in Oncology;2024-08-15

3. Radiological, pathological and surgical outcomes after neoadjuvant endocrine treatment in patients with ER-positive/HER2-negative breast cancer with a clinical high risk and a low-risk 70-gene signature;The Breast;2024-06

4. Favorable outcome of neoadjuvant endocrine treatment than surgery‐first in female HR‐positive/HER2‐negative breast cancer patients—A NCDB analysis (2010–2016);Cancer Medicine;2024-06

5. Squalene Epoxidase: Its Regulations and Links with Cancers;International Journal of Molecular Sciences;2024-03-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3